A different method of evaluation of the ERSPC trial confirms that prostate-specific antigen testing has a significant impact on prostate cancer mortality Journal Article


Authors: Zappa, M.; Puliti, D.; Hugosson, J.; Schröder, F. H.; Van Leeuwen, P. J.; Kranse, R.; Auvinen, A.; Carlsson, S.; Kwiatkowski, M.; Nelen, V.; Borda, A. P.; Roobol, M. J.; Villers, A.
Article Title: A different method of evaluation of the ERSPC trial confirms that prostate-specific antigen testing has a significant impact on prostate cancer mortality
Abstract: The advantages and disadvantages of two different methods of analyzing the European Randomized Study of Screening for Prostate Cancer (ERSPC) trial with respect to the effect of prostate-specific antigen (PSA) screening on prostate cancer (PCa) mortality (ie, disease-specific mortality analysis and excess mortality analysis) are discussed in depth. The traditional disease-specific mortality is the best end point, but it could be biased by misclassification of causes of death, and it does not take into account the possible effect of the screening process on other causes of death. Excess mortality analysis overcomes these problems, but the results could be biased if the expected mortality is not corrected for attendance status. Both methods, when applied to the ERSPC trials, demonstrate that no increase in non-PCa mortality occurred in the screening group and confirm that PSA screening decreases PCa mortality. © 2013 European Association of Urology.
Keywords: screening; excess mortality
Journal Title: European Urology
Volume: 66
Issue: 3
ISSN: 0302-2838
Publisher: Elsevier Science, Inc.  
Date Published: 2014-09-01
Start Page: 401
End Page: 403
Language: English
DOI: 10.1016/j.eururo.2013.12.055
PROVIDER: scopus
PUBMED: 24412230
PMCID: PMC5615402
DOI/URL:
Notes: Cited By (since 1996):2 -- Export Date: 2 September 2014 -- CODEN: EUURA -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Sigrid Viktoria Carlsson
    221 Carlsson